Optimizing Research Progress Hope And New Cures Act or the ORPHAN Cures Act
This bill modifies certain provisions under the Medicare Drug Price Negotiation Program with respect to orphan drugs.
The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The program does not apply to orphan drugs that are approved to treat only one rare disease or condition.
The bill modifies these provisions so as to exclude any period in which a drug was an orphan drug from market approval calculations. It also excludes orphan drugs that are approved to treat more than one rare disease or condition from the program.
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 946 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. R. 946
To amend title XI of the Social Security Act to expand and clarify the
exclusion for orphan drugs under the Drug Price Negotiation Program.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
February 4, 2025
Mr. Joyce of Pennsylvania (for himself, Mr. Davis of North Carolina,
Mr. Hern of Oklahoma, Mr. Peters, Mrs. Miller-Meeks, Mr. Keating, Mr.
Hudson, Mr. Thanedar, Mr. Bilirakis, and Mr. Gottheimer) introduced the
following bill; which was referred to the Committee on Energy and
Commerce, and in addition to the Committee on Ways and Means, for a
period to be subsequently determined by the Speaker, in each case for
consideration of such provisions as fall within the jurisdiction of the
committee concerned
_______________________________________________________________________
A BILL
To amend title XI of the Social Security Act to expand and clarify the
exclusion for orphan drugs under the Drug Price Negotiation Program.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Optimizing Research Progress Hope
And New Cures Act'' or the ``ORPHAN Cures Act''.
SEC. 2. EXPANDING AND CLARIFYING THE EXCLUSION FOR ORPHAN DRUGS UNDER
THE DRUG PRICE NEGOTIATION PROGRAM.
Section 1192(e) of the Social Security Act (42 U.S.C. 1320f-1(e))
is amended--
(1) in paragraph (1), by adding at the end the following
new subparagraph:
``(C) Treatment of former orphan drugs.--In
calculating the amount of time that has elapsed with
respect to the approval of a drug or licensure of a
biological product under subparagraph (A)(ii) and
subparagraph (B)(ii), respectively, the Secretary shall
not take into account any period during which such drug
or product was a drug described in paragraph (3)(A).'';
and
(2) in paragraph (3)(A)--
(A) by striking ``only one rare disease or
condition'' and inserting ``one or more rare diseases
or conditions''; and
(B) by striking ``such disease or condition'' and
inserting ``one or more rare diseases or conditions (as
such term is defined in section 526(a)(2) of the
Federal Food, Drug, and Cosmetic Act)''.
<all>
Introduced in House
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsor introductory remarks on measure. (CR H535-536)
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line